EGFR and neoplasm: All enrolled patients received EGFR-TKI as first-line treatment, and 55 (15.8%) underwent surgical resection of the primary tumor, including 44 patients with tumor resection and partial EGFR-TKI response, three patients with primary tumor resection at the time of diagnosis, five patients with surgical resection for post-operative loco-regional recurrence, and three patients with surgery for loco-regional progression after EGFR-TKI use.